JNJ - Johnson & Johnson Stock Price, Fair Value and News

146.85USD-1.68 (-1.13%)Market Closed

Market Summary

USD146.85-1.68

Market Closed

-1.13%

JNJ Stock Price

View Fullscreen

JNJ RSI Chart

JNJ Valuation

Market Cap

353.7B

Price/Earnings (Trailing)

10.06

Price/Sales (Trailing)

4.15

EV/EBITDA

15.3

Price/Free Cashflow

19.38

JNJ Price/Sales (Trailing)

JNJ Profitability

EBT Margin

17.69%

Return on Equity

51.11%

Return on Assets

20.98%

Free Cashflow Yield

5.16%

JNJ Fundamentals

JNJ Revenue

Revenue (TTM)

85.2B

Rev. Growth (Yr)

7.3%

Rev. Growth (Qtr)

0.21%

JNJ Earnings

Earnings (TTM)

35.2B

Earnings Growth (Yr)

15.03%

Earnings Growth (Qtr)

-84.44%

Breaking Down JNJ Revenue

Last 7 days

2.6%

Last 30 days

-4.3%

Last 90 days

-6.9%

Trailing 12 Months

-10.1%

How does JNJ drawdown profile look like?

JNJ Financial Health

Current Ratio

1.16

Debt/Equity

0.38

Debt/Cashflow

0.88

JNJ Investor Care

Dividend Yield

3.2%

Dividend/Share (TTM)

4.7

Buy Backs (1Y)

7.51%

Diluted EPS (TTM)

13.81

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	81.0B	82.3B	83.7B	85.2B
2022	76.3B	73.2B	69.8B	80.0B
2021	84.2B	89.2B	91.4B	78.7B
2020	82.7B	80.5B	80.9B	82.6B
2019	81.6B	81.3B	81.7B	82.1B
2018	78.7B	80.7B	81.4B	81.6B
2017	72.2B	72.5B	74.4B	76.5B
2016	70.2B	70.9B	71.6B	71.9B
2015	73.6B	71.9B	70.5B	70.1B
2014	71.9B	73.5B	74.4B	74.3B
2013	68.6B	70.0B	70.5B	71.3B
2012	65.0B	64.9B	65.9B	67.2B
2011	62.1B	63.4B	64.4B	65.0B
2010	62.5B	62.6B	62.5B	61.6B
2009	62.6B	61.4B	60.5B	61.9B
2008	0	62.0B	62.9B	63.7B
2007	0	0	0	61.1B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Johnson & Johnson

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 13, 2024	broadhurst vanessa	sold	-1,441,760	162	-8,891	evp, global corp affairs
Feb 13, 2024	duato joaquin	sold (taxes)	-237,880	157	-1,507	ceo and chairman of the board
Feb 13, 2024	wolk joseph j	acquired	-	-	1,780	exec vp, cfo
Feb 13, 2024	broadhurst vanessa	acquired	-	-	408	evp, global corp affairs
Feb 13, 2024	hait william	acquired	-	-	834	see remarks
Feb 13, 2024	swanson james d.	sold (taxes)	-30,780	157	-195	evp, cio
Feb 13, 2024	broadhurst vanessa	sold (taxes)	-32,990	157	-209	evp, global corp affairs
Feb 13, 2024	forminard elizabeth	acquired	-	-	651	executive vp, general counsel
Feb 13, 2024	decker robert j	sold (taxes)	-13,575	157	-86.00	vp corporate controller
Feb 13, 2024	fasolo peter	sold (taxes)	-74,820	157	-474	exec vp, chief hr officer

Which funds bought or sold JNJ recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	Orca Investment Management, LLC	added	21.83	567,027	3,037,410	2.84%
Apr 24, 2024	Archford Capital Strategies, LLC	reduced	-3.94	-64,918	2,063,890	0.35%
Apr 24, 2024	Gemmer Asset Management LLC	added	0.03	9,151	965,891	0.11%
Apr 24, 2024	DekaBank Deutsche Girozentrale	added	1.97	21,244,000	709,442,000	1.32%
Apr 24, 2024	National Mutual Insurance Federation of Agricultural Cooperatives	unchanged	-	131,950	14,395,300	0.15%
Apr 24, 2024	BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC	added	3.31	29,558	726,180	0.16%
Apr 24, 2024	Avitas Wealth Management LLC	added	1.22	120,924	5,719,830	0.87%
Apr 24, 2024	Verity & Verity, LLC	sold off	-100	-13,944,200	-	-%
Apr 24, 2024	Carmichael Hill & Associates, Inc.	reduced	-1.65	-25,327	3,392,240	1.34%
Apr 24, 2024	Greylin Investment Management, Inc	reduced	-0.5	51,149	12,095,200	1.94%

Are Funds Buying or Selling JNJ?

Are funds buying JNJ calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own JNJ

No. of Funds

Unveiling Johnson & Johnson's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	9.53%	229,372,559	SC 13G/A
Jan 30, 2024	state street corp	5.52%	132,996,283	SC 13G/A
Jan 26, 2024	blackrock inc.	7.7%	186,308,341	SC 13G/A
Feb 10, 2023	state street corp	5.45%	142,447,944	SC 13G/A
Feb 09, 2023	vanguard group inc	9.44%	246,826,621	SC 13G/A
Jan 31, 2023	blackrock inc.	7.6%	198,802,769	SC 13G/A
Feb 14, 2022	state street corp	5.51%	144,996,127	SC 13G/A
Feb 10, 2022	vanguard group inc	8.92%	234,782,632	SC 13G/A
Feb 01, 2022	blackrock inc.	7.6%	200,021,352	SC 13G/A
Feb 12, 2021	state street corp	5.47%	144,029,634	SC 13G

Recent SEC filings of Johnson & Johnson

View All Filings

Date Filed	Form Type	Document
Apr 16, 2024	8-K	Current Report
Apr 16, 2024	8-K/A	Current Report
Apr 10, 2024	3	Insider Trading
Apr 10, 2024	SC 13G	Major Ownership Report
Apr 05, 2024	DFAN14A	DFAN14A
Mar 27, 2024	PX14A6G	PX14A6G
Mar 13, 2024	DEFA14A	DEFA14A
Mar 13, 2024	DEFA14A	DEFA14A
Mar 13, 2024	DEF 14A	DEF 14A
Mar 13, 2024	ARS	ARS

Peers (Alternatives to Johnson & Johnson)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	353.7B	85.2B	-4.29%	-10.06%	10.06	4.15	6.46%	95.94%
MRK	330.8B	60.1B	1.36%	9.00%	906.27	5.5	1.40%	-97.49%
AMGN	144.4B	28.2B	-2.78%	11.49%	21.5	5.12	7.09%	2.52%
PFE	142.6B	46.5B	-4.27%	-33.23%	-102.73	3.06	42.59%	-114.62%
GILD	81.3B	27.1B	-7.58%	-21.63%	14.36	3	-0.60%	23.36%
TEVA	14.8B	15.8B	-7.47%	58.08%	-25.76	0.94	6.17%	76.47%
MID-CAP
PRGO	4.2B	4.7B	0.71%	-13.71%	-333.24	0.91	4.58%	90.97%
ALKS	4.1B	1.7B	-9.74%	-19.21%	11.49	2.46	49.61%	324.78%
BHC	3.1B	8.8B	-9.70%	20.22%	-5.32	0.36	7.79%	-163.11%
AMPH	2.0B	644.4M	-6.03%	4.38%	14.27	3.05	29.14%	50.51%
SMALL-CAP
TLRY	1.4B	743.2M	-14.42%	-17.86%	-3.85	1.82	24.65%	80.36%
TXMD	21.6M	1.3M	-15.72%	-46.54%	-2.1	16.56	-98.14%	-109.18%
ACRX	16.3M	-	-17.24%	40.47%	-0.89	0.22	2882.68%	-138.52%
AGRX	2.7M	19.6M	-33.33%	-94.15%	-0.19	0.14	80.00%	43.08%
ACOR	683.2K	117.6M	-96.48%	-95.45%	0	0.01	-0.79%	-283.60%

Johnson & Johnson News

Latest updates

Johnson & Johnson Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	0.2%	21,395	21,351	21,519	20,894	19,939	19,996	20,215	19,840	9,769	23,338	23,312	22,321	22,475	21,082	18,336	20,691	20,747	20,729	20,562	20,021	20,394
Gross Profit	-1.0%	14,597	14,745	15,057	14,207	13,855	13,824	13,893	13,822	8,267	16,088	15,725	15,258	14,661	14,110	11,757	13,629	13,613	13,862	13,622	13,406	13,433
S&GA Expenses	-15.6%	4,560	5,400	6,665	6,138	4,223	4,975	6,226	5,938	2,613	6,000	6,073	5,432	6,457	5,431	4,993	5,203	6,039	5,374	5,546	5,219	5,991
EBITDA Margin	2.5%	0.27*	0.27*	0.26*	0.24*	0.32*	0.31*	0.29*	0.30*	0.32*	0.30*	0.31*	0.30*	-	-	-	-	-	-	-	-	-
Interest Expenses	-55.7%	85.00	192	346	215	177	51.00	38.00	10.00	60.00	20.00	40.00	63.00	87.00	44.00	45.00	25.00	85.00	48.00	83.00	102	250
Income Taxes	-68.4%	287	908	1,618	-669	501	862	1,026	713	-421	182	384	1,232	-91.00	847	314	713	208	-106	1,434	673	80.00
Earnings Before Taxes	-7.5%	4,826	5,217	6,306	-1,287	3,840	5,172	5,144	5,203	1,238	3,849	6,662	7,429	1,647	4,401	3,940	6,509	4,218	1,647	7,041	4,422	3,122
EBT Margin	5.2%	0.18*	0.17*	0.17*	0.16*	0.24*	0.24*	0.21*	0.22*	0.24*	0.21*	0.23*	0.21*	-	-	-	-	-	-	-	-	-
Net Income	-84.4%	4,049	26,028	5,144	-68.00	3,520	4,458	4,814	5,149	4,736	3,667	6,278	6,197	1,738	3,554	3,626	5,796	4,010	1,753	5,607	3,749	3,042
Net Income Margin	-0.2%	0.41*	0.41*	0.14*	0.14*	0.21*	0.21*	0.19*	0.21*	0.22*	0.20*	0.20*	0.18*	-	-	-	-	-	-	-	-	-
Free Cashflow	-3.8%	6,274	6,522	3,058	2,394	3,763	5,332	4,718	3,372	4,317	7,543	4,501	3,397	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	0.9%	167,558	166,061	191,686	195,969	187,378	175,124	177,724	178,355	182,018	179,228	176,440	172,557	174,894	170,693	158,380	155,017	157,728	155,521	155,117	150,027	152,954
Current Assets	-0.4%	53,495	53,703	60,567	64,388	55,294	65,236	63,847	60,424	60,979	59,889	53,769	52,533	51,237	57,578	45,892	44,226	45,274	44,333	41,799	41,987	46,033
Cash Equivalents	10.8%	21,859	19,728	21,183	19,170	12,889	11,355	10,983	10,463	14,487	17,604	14,332	12,671	13,985	18,965	11,174	15,530	17,305	16,249	14,376	14,734	18,107
Inventory	-0.2%	11,181	11,198	12,888	12,809	10,268	11,675	11,437	10,990	10,387	10,387	10,100	9,952	9,344	9,599	9,424	8,868	9,020	9,173	9,263	9,086	8,599
Net PPE	5.7%	19,898	18,821	20,576	20,174	17,982	18,152	18,354	18,701	18,962	18,478	18,632	18,367	18,766	17,855	17,598	17,401	17,658	17,048	17,248	17,000	17,035
Goodwill	1.2%	36,558	36,124	45,440	45,575	36,047	33,383	34,166	34,935	25,436	35,569	35,819	200	36,393	1,200	33,890	200	33,639	33,291	33,661	2,000	30,453
Liabilities	4.2%	98,784	94,833	115,277	125,100	110,574	100,525	101,367	103,646	107,995	108,956	106,860	106,723	111,616	106,220	95,402	93,723	98,257	97,311	94,332	91,072	93,202
Current Liabilities	4.3%	46,282	44,370	54,170	60,373	55,802	45,543	44,821	43,390	45,226	44,561	38,721	40,932	42,493	38,847	36,772	33,689	35,964	35,162	31,353	29,111	31,230
Short Term Borrowings	-10.8%	3,451	3,870	11,701	17,979	12,756	4,424	4,305	4,297	3,766	3,798	3,173	3,350	2,631	5,078	5,332	2,190	1,202	2,299	1,719	1,708	2,796
Long Term Debt	-0.7%	25,881	26,051	33,901	34,928	26,886	27,603	28,292	28,851	29,985	30,130	30,310	30,263	32,635	7,500	25,062	25,393	26,494	26,919	27,699	27,660	27,684
LT Debt, Non Current	-0.7%	25,881	26,051	33,901	34,928	26,886	27,603	28,292	28,851	29,985	30,130	30,310	30,263	32,635	7,500	25,062	25,393	26,494	26,919	27,699	27,660	27,684
Shareholder's Equity	-3.4%	68,774	71,228	76,409	70,869	76,804	74,599	76,357	74,709	74,023	70,272	69,580	65,834	63,278	64,473	62,978	61,294	59,471	58,210	60,785	58,955	59,752
Retained Earnings	0.9%	153,843	152,536	129,381	124,558	128,345	127,917	126,216	124,380	123,060	121,092	120,154	116,508	113,890	114,831	113,898	112,901	110,659	109,242	109,809	106,650	106,216
Accumulated Depreciation	-100.0%	-	26,805	30,642	30,193	25,552	28,529	28,790	29,001	28,717	28,869	28,569	28,063	28,038	27,307	26,458	25,846	25,674	25,577	25,657	25,262	24,816
Shares Outstanding	0.4%	2,534	2,523	2,602	2,606	2,625	2,629	2,630	2,629	2,632	2,633	2,632	2,632	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	1,260	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	430,000	-	-	-	472,000	-	-	-	445,000	-	-	-	363,000	-	-	-	368,000	-	-

Cashflow (Last 12 Months)

(In Millions)

Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	5.0%	7,863	7,489	4,182	3,257	5,350	6,284	5,581	3,979	5,732	8,290	5,314	4,074	8,343	8,383	3,452	3,358	6,398	7,527	5,948	3,543	6,244
Share Based Compensation	-39.9%	178	296	382	306	213	281	366	278	215	259	354	307	160	256	326	263	160	245	314	258	156
Cashflow From Investing	-147.3%	-1,202	2,541	-3,776	3,315	-4,397	-1,701	-2,639	-3,634	-5,360	-2,719	-419	-185	-7,903	-4,819	-7,522	-581	-1,344	-1,645	-1,788	-1,417	2,228
Cashflow From Financing	58.9%	-4,655	-11,317	-5,991	6,138	1,700	-3,925	-2,261	-4,385	-3,436	-2,207	-3,279	-5,125	-5,644	4,196	-357	-4,315	-4,072	-3,893	-4,534	-5,516	-6,389
Buy Backs	-76.5%	216	920	381	3,537	1,320	2,165	973	1,577	996	391	631	1,438	321	483	706	1,711	426	1,628	2,486	2,206	3,808

JNJ Income Statement

2023-12-31

Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2023	Jan. 01, 2023	Jan. 02, 2022
Income Statement [Abstract]
Sales to customers	$ 85,159	$ 79,990	$ 78,740
Cost of products sold	26,553	24,596	23,402
Gross profit	58,606	55,394	55,338
Selling, marketing and administrative expenses	21,512	20,246	20,118
Research and development expense	15,085	14,135	14,277
In-process research and development impairments	313	783	900
Interest income	(1,261)	(490)	(53)
Interest expense, net of portion capitalized	772	276	183
Other (income) expense, net	6,634	810	526
Restructuring	489	275	209
Earnings before provision for taxes on income	15,062	19,359	19,178
Provision for taxes on income	1,736	2,989	1,377
Net earnings from continuing operations	13,326	16,370	17,801
Net earnings from discontinued operations	21,827	1,571	3,077
Net earnings	$ 35,153	$ 17,941	$ 20,878
Net earnings per share
Basic net earnings per share from continuing operations (in dollars per share)	$ 5.26	$ 6.23	$ 6.76
Basic net earnings per share from discontinued operations (in dollars per share)	8.62	0.60	1.17
Basic (in dollars per share)	13.88	6.83	7.93
Diluted net earnings per share from continuing operations (in dollars per share)	5.20	6.14	6.66
Diluted net earnings per share from discontinuing operations (in dollars per share)	8.52	0.59	1.15
Diluted (in dollars per share)	$ 13.72	$ 6.73	$ 7.81
Average shares outstanding
Basic (in shares)	2,533.5	2,625.2	2,632.1
Diluted (in shares)	2,560.4	2,663.9	2,674.0

JNJ Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2023	Jan. 01, 2023
Current assets:
Cash and cash equivalents	$ 21,859	$ 12,889
Marketable securities	1,068	9,392
Accounts receivable trade, less allowances $166 (2022, $169)	14,873	14,039
Inventories	11,181	10,268
Prepaid expenses and other receivables	4,514	2,876
Total current assets of discontinued operations	0	5,830
Total current assets	53,495	55,294
Property, plant and equipment, net	19,898	17,982
Intangible assets, net	34,175	38,489
Goodwill	36,558	36,047
Deferred taxes on income	9,279	8,947
Other assets	14,153	9,212
Noncurrent assets of discontinued operations	0	21,407
Total assets	167,558	187,378
Current liabilities
Loans and notes payable	3,451	12,756
Accounts payable	9,632	9,889
Accrued liabilities	10,212	10,719
Accrued rebates, returns and promotions	16,001	13,579
Accrued compensation and employee related obligations	3,993	3,049
Accrued taxes on income	2,993	2,220
Current liabilities of discontinued operations	0	3,590
Total current liabilities	46,282	55,802
Long-term debt	25,881	26,886
Deferred taxes on income	3,193	3,991
Employee related obligations	7,149	6,542
Long-term taxes payable	2,881	4,306
Other liabilities	13,398	10,146
Noncurrent liabilities of discontinued operations	0	2,901
Total liabilities	98,784	110,574
Commitments and Contingencies
Shareholders’ equity
Preferred stock — without par value (authorized and unissued 2,000,000 shares)	0	0
Common stock — par value $1.00 per share (Note 12) (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)	3,120	3,120
Accumulated other comprehensive income (loss)	(12,527)	(12,967)
Retained earnings and Additional-paid-in-capital	153,843	128,345
Less: common stock held in treasury, at cost (Note 12) (712,765,000 shares and 506,246,000 shares)	75,662	41,694
Total shareholders’ equity	68,774	76,804
Total liabilities and shareholders’ equity	$ 167,558	$ 187,378

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. This segment also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment provides products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes, and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment offers electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and contact lenses and ophthalmic technologies related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

CEO	Mr. Joaquin Duato
WEBSITE	jnj.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	65535

Johnson & Johnson Frequently Asked Questions

What is the ticker symbol for Johnson & Johnson? What does JNJ stand for in stocks?

JNJ is the stock ticker symbol of Johnson & Johnson. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Johnson & Johnson (JNJ)?

As of Wed Apr 24 2024, market cap of Johnson & Johnson is 357.85 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of JNJ stock?

You can check JNJ's fair value in chart for subscribers.

What is the fair value of JNJ stock?

You can check JNJ's fair value in chart for subscribers. The fair value of Johnson & Johnson is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Johnson & Johnson is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for JNJ so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Johnson & Johnson a good stock to buy?

The fair value guage provides a quick view whether JNJ is over valued or under valued. Whether Johnson & Johnson is cheap or expensive depends on the assumptions which impact Johnson & Johnson's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for JNJ.

What is Johnson & Johnson's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, JNJ's PE ratio (Price to Earnings) is 10.18 and Price to Sales (PS) ratio is 4.2. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. JNJ PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Johnson & Johnson's stock?

In the past 10 years, Johnson & Johnson has provided 0.066 (multiply by 100 for percentage) rate of return.